Health Canada Approves Otsuka and Lundbeck’s REXULTI™ (brexpiprazole) as a Treatment for Schizophrenia in Adults
REXULTI™ was studied in more than 2700 subjects with schizophrenia in phase II and III clinical trials, and the approval was supported by three completed placebo-controlled clinical phase III studies in the now-approved indication. In clinical trials, REXULTI™ was found to significantly improve both positive and negative symptoms.1,2,3
The efficacy, safety and tolerability of REXULTI™ was established in two 6-week, fixed-dose, phase III randomized, placebo-controlled clinical trials and one 52-week randomized withdrawal trial in subjects with schizophrenia who were experiencing an acute exacerbation of psychotic symptoms.1,2,3
“Brexpiprazole, a new treatment option for schizophrenia, with a unique mechanism of action provides us with new hope for patients suffering from this devastating illness,” said Dr Ofer Agid, associate professor of psychiatry, Schizophrenia Program, Center for Addiction and Mental Health (CAMH), Department of Psychiatry, University of Toronto, Toronto, Ontario.
Schizophrenia is a severely debilitating and progressive mental illness4 affecting approximately 1% of the Canadian population—more than 350,000 Canadians.5,6,7
“It is always exciting to have a new treatment option for patients with schizophrenia since this is an illness where there are still patients who are not able to achieve remission”, says Chris Summerville, CEO of the Schizophrenia Society of Canada.
Due to the underlying heterogeneity in the manifestations of schizophrenia, and differences in patient tolerability and response to treatment, patients are in need of additional treatment options.
“Psychiatric diseases remain a challenging therapeutic area where many people are unsatisfied with their treatments,” noted Allison Rosenthal, general manager of Otsuka Canada Pharmaceutical Inc. “Today’s approval of REXULTI is another example of Otsuka and Lundbeck’s commitment to bringing new therapeutic alternatives to the mental health community.”
“All treatment options require healthcare providers, patients and caregivers to balance efficacy and tolerability in managing their diseases,” said Sylvie Pilon, vice president and general manager, Lundbeck Canada. “We are proud to introduce REXULTI to help adult patients living with schizophrenia.”
REXULTI™ is given in a once-daily oral dose with a well-defined titration schedule that can be taken with or without food.8
REXULTI™ (brexpiprazole) is a new molecule (i.e., not a metabolite or isomer) discovered by Otsuka and co-developed by Otsuka and Lundbeck. The mechanism of action for REXULTI™ in the treatment of schizophrenia is unknown. However, the efficacy of REXULTI™ may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, REXULTI™ exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.9
Otsuka Pharmaceutical Co., Ltd., is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada. OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardiovascular health, oncology and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.
OCPI is part of Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. Otsuka Holdings had consolidated sales of approximately USD 11 billion in 2016. Otsuka welcomes you to visit its global pharmaceutical website at https://www.otsuka.co.jp/en and the website of OCPI at http://otsukacanada.com.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, Lundbeck has been at the forefront of research within neuroscience. Lundbeck’s development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. The key areas of focus are Alzheimer’s disease, depression/anxiety, Parkinson’s disease and schizophrenia. Lundbeck’s employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. The Lundbeck pipeline consists of several late-stage development programs and products are available in more than 100 countries. Lundbeck has research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of approximately DKK 15.6 billion in 2016 (EUR 2.0 billion; USD 2.2 billion).
A division of Denmark-based H. Lundbeck A/S, Lundbeck Canada Inc. has been a trusted source of innovative new treatments for Canadians since 1995 with headquarters in Montreal. Originally focused on providing products for the treatment of diseases such as depression, anxiety, Alzheimer’s disease and schizophrenia, Lundbeck Canada also offers new cancer therapies for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. A patient-focused partner in Canadian health care, Lundbeck Canada’s mission is to improve the quality of life for people living with brain diseases and cancer.
REXULTI™ is a trademark of Otsuka Pharmaceutical Co., Ltd., used under license by Otsuka Canada Pharmaceutical Inc.
Otsuka Canada Pharmaceutical Inc.
Vice-President & General Manager
1. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S et al. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164 (1-3): 127-135.
2. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S et al. (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-Week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 172 (9): 870-880.
3. Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S et al. (2016) Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacology (2017) 20(1): 11-21.
4. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th Ed. Arlington, VA: American Psychiatric Association.
5. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063-72.
6. Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D et al. (2005) The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 21 (12): 2017-2028.
7. Mood Disorders Society of Canada. Quick facts on mental illness and addictions in Canada, 3rd Edition, Nov 2009. (Accessed December 19, 2016, at https://mdsc.ca/quick-facts/.)
8. Otsuka Canada Pharmaceutical Inc. REXULTITM (brexpiprazole) product monograph. February 16, 2017.
9. Maeda, K. et al. Pharmacological profile of brexpiprazole (OPC-2471234712): a novel serotonin-dopamine activity modulator. Poster presentation at American Psychiatric Association annual meeting, May 3-7, 2014.